Antiretroviral combination prevents HIV transmission but dangerous for some infants
Although drug regimens such as the protease inhibitor lopinavir-ritonavir may have lowered the HIV transmission rates in newborns to less than 1%, a study finds that postnatal treatment with the combination was more likely to cause adrenal dysfunction in newborns when compared with a zidovudine-based treatment. Read about the nuances of the study and the researchers? recommendations.
Treatment guidelines call for highly active antiretroviral therapy (HAART) during pregnancy both for the benefit of maternal health and to decrease the risk of vertical transmission of HIV-1 virus to the baby. That practice has been highly effective, dropping HIV transmission rates to newborns to less than 1% for mothers treated during pregnancy.
A new French study suggests, however, that although drug regimens such as the protease inhibitor lopinavir-ritonavir may be preventing babies from contracting HIV, postnatal treatment with the combination was more likely to cause adrenal dysfunction in newborns when compared with a zidovudine-based treatment. In premature infants, the treatment caused life-threatening adrenal insufficiency, researchers said.
Combinations of antiretrovirals often are used as postexposure prophylaxis when HIV treatment of the mother has been less than optimal because of late diagnosis or persistent viral replication at delivery. According to the researchers, most commonly prescribed is the protease inhibitor lopinavir, with its pharmacologic booster, ritonavir (lopinavir-ritonavir). Lopinavir-ritonavir is licensed in the United States for HIV-infected newborns older than 14 days and in Europe for children older than 2 years.
Researchers recommended that lopinavir-ritonavir and, more generally, ritonavir boosting should be used with caution, if at all, in premature infants. Electrolytes should be regularly monitored in full-term infants if the drug regimen is used, they said.
The researchers also called for more study on prenatal ritonavir exposure and whether prolonged exposure via breast milk also can cause adrenal issues in infants.
Stress ulcer prophylaxis does not provide prevention of gastrointestinal bleeding in neonates
December 4th 2023In a poster abstract presented at the American Society of Health-System Pharmacists Midyear Clinical Meeting & Exhibition held in Anaheim, California, stress ulcer prophylaxis (SUP) did not appear to provide benefit for prevention of gastrointestinal bleeding and did not increase SUP-associated adverse effects.
Hematocrit levels in newborns: EPP vs DCC study reveals surprising findings
November 15th 2023A recent study in JAMA Network Open investigates the impact of extrauterine placental perfusion versus delayed cord clamping on hematocrit levels in newborns, shedding light on potential alternatives for optimizing infant outcomes during birth.
Preterm infant HRQOL: Long-term impacts and determinants
October 21st 2023A recent study was highlighted at the 2023 American Academy of Pediatrics National Conference & Exhibition that shed light on the long-term impact of very preterm birth on the health-related quality of life (HRQOL) of infants and identified key determinants.
Associations between prenatal metal mixture exposure and negative infant outcomes
September 19th 2023Francheska M. Merced-Nieves, PhD, Assistant professor, Departments of Pediatrics and the Institute for Exposomic Research of Environmental Medicine & Public Health, Icahn School of Medicine at Mount Sinai, explains the associations prenatal exposure to a metal mixture and the potential negative effects for the infant.
